Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Vaccine

• Publication date

  2010-11-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2010.09.046PMID 20883737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines

  2009cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity.

  2008cited by this paper
• Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA‐electroporated B cells

  2008cited by this paper
• Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

  2008cited by this paper
• Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

  2007cited by this paper
• Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.

  2007cited by this paper
• Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.

  2007cited by this paper
• A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.

  2007cited by this paper
• Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)‐expressing colon cancer using genetically modified dendritic cells that express CEA and T helper‐type 1 cytokines in CEA transgenic mice

  2007cited by this paper
• Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine

  2007cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• The role of stroma in immune recognition and destruction of well-established solid tumors.

  2006cited by this paper
• Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors

  2006cited by this paper
• Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.

  2006cited by this paper
• Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer

  2006cited by this paper
• Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen–Derived HLA-A2–Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer

  2005cited by this paper
• Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation

  2005cited by this paper
• Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules

  2005cited by this paper
• Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

  2005cited by this paper
• Cancer Immunotherapy: A Treatment for the Masses

  2004cited by this paper
• Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer

  2004influential reference
• Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide–pulsed dendritic cells

  2004cited by this paper
• In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses.

  2003cited by this paper
• Immunotherapy for colorectal cancer

  2003cited by this paper
• Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor‐specific antitumor effect in vivo

  2002cited by this paper
• Exploiting dendritic cells to improve vaccine efficacy.

  2002cited by this paper
• Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro1

  2000cited by this paper
• Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo

  1997cited by this paper
• Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.

  1997cited by this paper
• CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.

  1996cited by this paper
• Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

  1996cited by this paper
• Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in TH1 cells.

  1995cited by this paper
• Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

  1992cited by this paper
• Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives

  1991cited by this paper
• Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine.

  1990cited by this paper
• Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer

  1989cited by this paper

• Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance

  2026cites this paper
• “Add More Arrows to Your Quiver”: The Role of Adding Another Chemotherapy Drug to Fluoropyrimidine and Long Term Radiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis

  2025cites this paper
• BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer.

  2024cites this paper
• PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies

  2023cites this paper
• OX40 as a novel target for the reversal of immune escape in colorectal cancer.

  2021cites this paper
• Gold Compounds and the Anticancer Immune Response

  2021cites this paper
• Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma

  2021cites this paper
• Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.

  2020cites this paper
• Combination Therapy

  2019cites this paper
• Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells

  2017cites this paper
• Combination of DC Vaccine and Conventional Chemotherapeutics.

  2016cites this paper
• Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model

  2014cites this paper
• Immunological off-target effects of standard treatments in gastrointestinal cancers.

  2014cites this paper
• P10. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model

  2014cites this paper
• Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise

  2013cites this paper
• ESAT‐6‐gpi DNA Vaccine Augmented the Specific Antitumour Efficacy Induced by the Tumour Vaccine B16F10‐ESAT‐6‐gpi/IL‐21 in a Mouse Model

  2013cites this paper
• Whole cell vaccines--past progress and future strategies.

  2012cites this paper
• Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy

  2012cites this paper
• Maturation of morphology, phenotype and functions of murine bone marrow-derived dendritic cells(DCs) induced by polysaccharide Kureha(PSK)

  2012cites this paper
• Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials.

  2012cites this paper
• Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse

  2012cites this paper
• NEGATIVE REGULATION OF REGULATORY T CELLS BY MYELOID-DERIVED SUPPRESSOR CELLS IN CANCER

  2011cites this paper
• Lipid-based cancer vaccines

  2011cites this paper
• Antitumor efficacy induced by a B16F10 tumor cell vaccine treated with mitoxantrone alone or in combination with reserpine and verapamil in mice.

  2011cites this paper
• The suppressive tumor microenvironment: a challenge in cancer immunotherapy.

  2011cites this paper
• Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat.

  2011cites this paper
• Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity.

  2011cites this paper